Trenbolone Acetate for Advanced Anabolic Use — Anabolic Steroids
Potent 19-nortestosterone derivative with 3x testosterone binding affinity. Veterinary compound not approved for human use.
Overview
Trenbolone Acetate is one of the most potent anabolic-androgenic steroids ever developed. Originally created for veterinary use (cattle implants under the brand Finaplix), it has never been approved for human use. Trenbolone binds the androgen receptor with approximately 3 times the affinity of testosterone and has an anabolic-to-androgenic rating of 500:500 (compared to testosterone's 100:100). It does NOT aromatize to estrogen, meaning it does not cause water retention or gynecomastia via estrogenic pathways. However, it binds progesterone and glucocorticoid receptors, which can cause unique side effects. The acetate ester provides a short half-life of approximately 3 days, requiring every-other-day injection. Trenbolone is associated with significant side effects including cardiovascular toxicity, insomnia, night sweats, anxiety, and severe HPTA suppression. Detection time can extend up to 2 years post-injection.
Indications
- Not FDA-approved for any human indication
- Advanced body composition optimization (non-medical)
- Lean mass accrual without water retention
- Strength and power enhancement
- Veterinary use: growth promotion in cattle (Finaplix implants)
- Recomposition: simultaneous fat loss and muscle gain
Mechanism of Action
Pursuit of dramatic body composition changes with acceptance of significant health risks (NOT medically indicated)
Dosing
| Compound | Dose | Frequency | Notes |
|---|---|---|---|
| Trenbolone Acetate | 50-75 mg | Every other day | Lower-range dosing for those experienced with AAS; always with testosterone base. NOT medically recommended |
| Trenbolone Acetate | 75-100 mg | Every other day | Standard non-medical dosing range reported in literature. Significant side effect risk |
Evidence Grade
GRADE D
Safety & Contraindications
- NOT approved for human use - veterinary compound only
- Schedule III controlled substance
- Extreme cardiovascular toxicity: significant negative lipid changes, left ventricular hypertrophy
- Severe insomnia, night sweats, and anxiety are common
- 'Tren cough' - acute bronchospasm immediately after injection (acetate ester)
- Profoundly suppresses natural testosterone - always requires testosterone base
- Strong progestogenic activity - can cause gynecomastia via prolactin pathway
- Highly hepatotoxic at supraphysiological doses
- Can cause renal stress and dark-colored urine (oxidized metabolites)
- Neurotoxic potential: aggression, mood disturbances, cognitive impairment
- Extremely long detection time: metabolites found up to 2 years post-injection
- Contraindicated in individuals with cardiovascular disease, liver disease, or psychiatric disorders
- No human clinical safety data - all safety information derived from case reports and veterinary studies